Why is "Aroxybutynin" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-06-03 20:01:59
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Aroxybutynin entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-06-03 and was most recently seen on 2026-06-03.
Wikipedia Overview
Oxybutynin, sold under the brand name Ditropan among others, is an anticholinergic medication primarily used to treat overactive bladder. It is widely considered a first-line therapy for overactive bladder due to its well-studied side effect profile, broad applicability, and continued efficacy over long periods of time. It works similar to tolterodine, darifenacin, and solifenacin, although it is usually preferred over these medications. It is commonly prescribed after some types of bladder surgery to reduce bladder spasms and catheter-associated discomfort. It is sometimes used off-label for treatment of hyperhidrosis, or excessive sweating. It has also been used off-label to treat bedwetting in children, but this use has declined, as it is most likely ineffective in this role. It is taken by mouth or applied to the skin.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Aroxybutynin and Atomoxetine (AD109) Reduces Obstructive Sleep Apnea Burden in Phase 3 SynAIRgy - HCPLive
-
Oral AD109 improves sleep apnea severity but tolerability remains a challenge - News-Medical
-
Once-nightly pill treats causes of airway collapse to control obstructive sleep apnea in large clinical trial - Medical Xpress
-
OSA severity decreases with oral aroxybutynin, atomoxetine combination over 26 weeks - Healio
-
Another Sleep Apnea Drug May Be on the Horizon for a Broader Population - MedPage Today
-
Oral aroxybutynin, atomoxetine combination lowers OSA severity over 51 weeks - Healio
-
Apnimed announces positive results in clinical trial of sleep apnea medication - American Academy of Sleep Medicine | AASM
-
Pivotal Phase 3 Topline Results for Neuromuscular-Targeting OSA Drug Candidate - Sleep Review
-
Apnimed’s IPO Bags $192M for What Could Become the First Oral Sleep Apnea Drug - MedCity News
-
SynAIRgy Phase 3 Trial Aims to Assess Pharmacological Activation of Upper Airway Muscles to Treat Obstructive Sleep Apnea | NeurologyLive - Clinical Neurology News and Neurology Expert Insights - NeurologyLive
-
Aroxybutynin plus atomoxetine novel oral therapy for obstructive sleep apnea: MARIPOSA phase 2b trial - Medical Dialogues
-
Aroxybutynin and atomoxetine combo good treatment option for sleep apnea in patients with low CPAP... - Medical Dialogues
-
Oral combination obstructive sleep apnea drug lowers disorder severity over 1 month - Healio
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.